Crohns Disease Cd Epidemiology Forecast Insight

DelveInsight’s ‘Crohn’s Disease (CD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CD epidemiology in the United States.

Geographies Covered

  • The United States

Study Period: 2018–2030

Crohn’s Disease (CD) Understanding

Crohn’s Disease (CD) Overview

Crohn’s Disease (CD) is a type of Inflammatory Bowel Disease (IBD). It causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Inflammation caused by CD can involve different areas of the digestive tract in different people. However, this type of IBD most commonly affects the small intestine and the start of the colon. CD can cause patches of inflammation that damage multiple layers of the GI tract wall. CD can be painful and sometimes may lead to life-threatening complications.

 

Crohn’s is sometimes described as a chronic condition. This means that it is ongoing and life-long. The disease runs a benign course with few flare-ups in many people, while other people may have more severe disease. CD is not infectious. Crohn’s can start at any age but usually appears for the first time between the ages of 10 and 40, although there is a small peak in the number of people diagnosed over 60. Crohn’s is often categorized according to which part or parts of the gut are most affected. Sometimes it can affect more than one part of the gut. There are different types of CD, each affecting different parts of the digestive tract including ileocolitis, ileitis, gastroduodenal Crohn’s disease, jejunoileitis, and Crohn’s colitis. The causes of CD are not yet well understood but genetic, immune response and environmental factors are suspected to contribute to CD development

 

Crohn’s symptoms may range from mild-to-severe and vary from person to person. Patients most often present with abdominal cramps, diarrhea, delayed growth (in prepubescent patients), weight loss, fever, anemia, a right lower quadrant abdominal mass (if a complication has developed in the ileal area), or perianal fistula. In addition to having symptoms in the GI tract, some people may also experience various symptoms in other parts of the body associated with CD.

 

Crohn’s Disease (CD) Diagnosis

Diagnosis of CD requires a complete assessment based on clinical history, physical examination, and complementary diagnostic tests, such as assays for serological and fecal biomarkers, blood tests. The doctor may recommend additional testing to look inside the GI tract and intestine. While these tests are more invasive than others, they are often done in an outpatient setting. Intestinal endoscopies are the most accurate methods for diagnosing CD and ruling out other possible conditions, such as ulcerative colitis, diverticular disease, or cancer.

 

Cross-sectional imaging refers to using computerized tomography (CT) scanning or magnetic resonance imaging (MRI) to evaluate the intestinal tract and surrounding structures for the presence of inflammation or complications such as strictures, fistulae, or abnormal fluid collections. There is no single test to confirm a Crohn’s diagnosis, and CD symptoms are often similar to other conditions, including bacterial infection. The doctors may also perform a differential diagnosis to rule out other conditions that can have some of the common symptoms of CD, such as abdominal pain and diarrhea.

Epidemiology Perspective by DelveInsight

The CD epidemiology division provides insights about the historical and current CD patient pool and forecasted trends for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

  • In the year 2020, the total prevalent case of CD was 825,165 cases in the United States which are expected to grow during the forecast period, i.e., 2021–2030.
  • In the United States, the total diagnosed cases of CD were 591,368 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021–2030.
  • In the United States, the total age-specific cases of CD were 351,273, 166,766, 67,416, and 5,914 cases for the age group less than 18–44, 45–64, 65–84, and ≥85 years, respectively in 2020.
  • In the United States, the total severity-specific cases of CD were 236,547, and 354,821 cases for mild and moderate to severe cases, respectively in 2020.
  • In the United States, the total treated cases of CD was 319,339 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted CD epidemiology [segmented as Total Prevalent Cases of CD, Total Diagnosed Cases of CD, Age-specific cases of CD, Severity-specific Cases of CD, and Treated cases of CD] in the United States from 2018 to 2030.

Scope of the Report

  • The CD report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The CD Report and Model provide an overview of the risk factors and global trends of CD in the United States.
  • The report provides insight about the historical and forecasted patient pool of CD in the United States.
  • The report helps to recognize the growth opportunities in the United States concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of CD.
  • The report provides the segmentation of the CD epidemiology by total prevalent cases in the United States.
  • The report provides the segmentation of the CD epidemiology by total diagnosed cases in the United States.
  • The report provides the segmentation of the CD epidemiology by age-specific cases in the United States.
  • The report provides the segmentation of the CD epidemiology by severity-specific cases in the United States.
  • The report provides the segmentation of the CD epidemiology by treated cases in the United States.

Report Highlights

  • 10-Year Forecast of CD epidemiology
  • The United States Coverage
  • Total Prevalent Cases of CD
  • Total Diagnosed Cases of CD
  • Age-Specific Cases of CD
  • Severity-Specific Cases of CD
  • Treated Cases of CD

KOL-Views

We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the United States concerning the patient population of CD?
  • What are the key findings of the CD epidemiology across the United States during the study period (2018–2030)?
  • What would be the total number of patients of CD across the United States during the study period (2018–2030)?
  • At what CAGR the patient population is expected to grow in the United States during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of CD?

Reasons to buy

The CD Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global CD market
  • Quantify patient populations in the global CD market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the gender that presents the best opportunities for CD therapeutics in the United States market covered
  • Understand the magnitude of CD population by its severity
  • The CD epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The CD Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Crohn’s Disease

3. SWOT Analysis of Crohn’s Disease

4. Epidemiology Methodology

5. Crohn’s Disease (CD): Disease Background and Overview

5.1. Introduction

5.2. Types of CD

5.3. Classification of CD

5.4. Signs and Symptoms of CD

5.5. Risk Factors and Causes of CD

5.6. Pathophysiology of CD

5.7. Complications of CD

6. Diagnosis of CD

6.1. Diagnostic Algorithm

6.2. Physical Exam

6.3. Diagnostic Tests

6.3.1. Routine Blood Tests

6.3.2. Stool Tests

6.4. Imaging Tests

6.4.1. Endoscopy

6.4.2. Cross-sectional imaging

6.5. Differential Diagnosis

6.5.1. Antibody blood tests (Biomarkers)

7. Diagnostic Guidelines of CD

7.1. American College of Gastroenterology (ACG) guidelines

8. Epidemiology and Patient Population

8.1. Epidemiology Key Findings

8.2. Assumptions and Rationale

8.3. The United States Epidemiology

8.3.1. Total Prevalent Cases of Crohn’s disease (CD) in the United States

8.3.2. Total Diagnosed Cases of Crohn’s disease (CD) in the United States

8.3.3. Age-Specific Cases of Crohn’s disease (CD) in the United States

8.3.4. Severity-specific Cases of Crohn’s disease (CD) in the United States

8.3.5. Treated cases of Crohn’s disease (CD) in the United States

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Crohn’s Disease Epidemiology

Table 2: Difference between Crohn’s Disease and Ulcerative Colitis

Table 3: Vienna and Montreal classification for CD

Table 4: Genes with functions associated with CD

Table 5: Cytokines associated with CD

Table 6: Total Prevalent Cases of Crohn’s disease (CD) in the United States (2018–2030)

Table 7: Total Diagnosed Cases of Crohn’s disease (CD) in the United States (2018–2030)

Table 8: Age-Specific Cases of Crohn’s disease (CD) in the United States (2018–2030)

Table 9: Severity-specific Cases of Crohn’s disease (CD) in the United States (2018–2030)

Table 10: Total Treated cases of Crohn’s disease (CD) in the United States (2018–2030)

List of Figures

Figure 1: CD SWOT Analysis

Figure 2: Epidemiology Methodology

Figure 3: Inflammatory bowel disease subsets

Figure 4: Difference between CD and Ulcerative Colitis

Figure 5: Types of CD

Figure 6: Signs and Symptoms

Figure 7: Causes and risk factors of CD

Figure 8: Immuno-mediated pathogenesis of CD

Figure 9: Local complications of CD

Figure 10: Systemic complications of CD

Figure 11: Diagnostic Algorithm

Figure 12: Capsule endoscopy

Figure 13: CT Scan

Figure 14: Total Prevalent Cases of Crohn’s disease (CD) in the United States (2018–2030)

Figure 15: Total Diagnosed Cases of Crohn’s disease (CD) in the United States (2018–2030)

Figure 16: Age-Specific Cases of Crohn’s disease (CD) in the United States (2018–2030)

Figure 17: Severity-specific Cases of Crohn’s disease (CD) in the United States (2018–2030)

Figure 18: Treated cases of Crohn’s disease (CD) in the United States (2018–2030)

Forward to Friend

Need A Quote